KYC is one time exercise with a SEBI registered intermediary while dealing in securities markets (Broker/ DP/ Mutual Fund etc.). | No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account.   |   Prevent unauthorized transactions in your account – Update your mobile numbers / email ids with your stock brokers. Receive information of your transactions directly from exchange on your mobile / email at the EOD | Filing Complaint on SCORES - QUICK & EASY a) Register on SCORES b) Mandatory details for filing complaints on SCORE - Name, PAN, Email, Address and Mob. no. c) Benefits - speedy redressal & Effective communication   |   BSE Prices delayed by 5 minutes... << Prices as on Nov 16, 2026 >>  ABB India 6885  [ -2.27% ]  ACC 1222.15  [ 0.17% ]  Ambuja Cements 382.5  [ -0.05% ]  Asian Paints 2581  [ 1.30% ]  Axis Bank 1340  [ 0.57% ]  Bajaj Auto 10709.9  [ -1.02% ]  Bank of Baroda 270.15  [ -1.24% ]  Bharti Airtel 2152  [ 2.16% ]  Bharat Heavy 429.6  [ -1.31% ]  Bharat Petroleum 305  [ 0.86% ]  Britannia Industries 4750  [ -0.11% ]  Cipla 1394  [ 0.07% ]  Coal India 398  [ -1.29% ]  Colgate Palm 1702  [ -0.62% ]  Dabur India 380.05  [ -0.25% ]  DLF 755  [ -0.08% ]  Dr. Reddy's Lab. 1380  [ 0.22% ]  GAIL (India) 186.55  [ -0.51% ]  Grasim Industries 3075  [ 1.82% ]  HCL Technologies 1382.4  [ 0.42% ]  HDFC Bank 816  [ 1.61% ]  Hero MotoCorp 5344  [ -0.67% ]  Hindustan Unilever 1997  [ 0.60% ]  Hindalco Industries 925  [ -2.05% ]  ICICI Bank 1583.4  [ -0.04% ]  Indian Hotels Co. 885  [ -0.56% ]  IndusInd Bank 912  [ -0.76% ]  Infosys 1143.7  [ 0.32% ]  ITC 294.8  [ 3.78% ]  Jindal Steel 1130  [ -2.77% ]  Kotak Mahindra Bank 493.2  [ 1.15% ]  L&T 4137.8  [ -0.03% ]  Lupin 1972.5  [ -0.38% ]  Mahi. & Mahi 3350  [ 0.42% ]  Maruti Suzuki India 12573.75  [ -2.36% ]  MTNL 25.24  [ -3.30% ]  Nestle India 1295.1  [ 2.42% ]  NIIT 71.93  [ -1.00% ]  NMDC 68.91  [ -1.42% ]  NTPC 321  [ 0.69% ]  ONGC 226.7  [ 0.62% ]  Punj. NationlBak 144.4  [ 0.98% ]  Power Grid Corpn. 262  [ 1.69% ]  Reliance Industries 1342  [ 0.18% ]  SBI 1090  [ 0.88% ]  Vedanta 253.2  [ -2.48% ]  Shipping Corpn. 264.85  [ -2.11% ]  Sun Pharmaceutical 1866.95  [ -0.74% ]  Tata Chemicals 612  [ 1.07% ]  Tata Consumer 1115.6  [ 3.39% ]  Tata Motors Passenge 262.2  [ -8.64% ]  Tata Steel 181.75  [ -2.81% ]  Tata Power Co. 345  [ -0.92% ]  Tata Consult. Serv. 2401  [ -0.37% ]  Tech Mahindra 1783.5  [ 1.03% ]  UltraTech Cement 12258.25  [ 1.32% ]  United Spirits 1441.3  [ 1.85% ]  Wipro 193.5  [ -0.51% ]  Zee Entertainment 71.66  [ -0.71% ]  

Company Information

Indian Indices

  • Loading....

Global Indices

  • Loading....

Forex

  • Loading....

WANBURY LTD.

16 November 2026 | 12:00

Industry >> Pharmaceuticals

Select Another Company

ISIN No INE107F01022 BSE Code / NSE Code 524212 / WANBURY Book Value (Rs.) 42.25 Face Value 10.00
Bookclosure 20/02/2025 52Week High 359 EPS 18.91 P/E 9.41
Market Cap. 622.52 Cr. 52Week Low 162 P/BV / Div Yield (%) 4.21 / 0.00 Market Lot 1.00
Security Type Other

DIRECTOR'S REPORT

You can view full text of the latest Director's Report for the company.
Year End :2026-03 

Your Directors have pleasure in presenting herewith the 38 Annual Report of the business and operations alongwith Audited
Financial Statements of the Company for the Financial Year ended 31 March, 2026.

FINANCIAL HIGHLIGHTS:

The summarised financial highlights for the year under review are as under:

(Rs. in Lakhs)

PARTICULARS

2025-2026

2024-2025

Total Revenue from operations

65,026.81

59,951.42

Other Income

93.72

349.33

Total Income

65,120.54

60,300.75

Total Expenses

58,779.96

57,345.68

Profit /(Loss) Before Exceptional Items & Tax

6,340.58

2,955.07

Exceptional Items - Labour code related Expense

(360.39)

-

Profit /(Loss) Before Tax

5,980.19

2,955.07

Less: Tax including deferred Tax

(633.27)

(97.94)

Net Profit / (Loss) after tax

6,613.47

3,053.01

TRANSFER TO RESERVES:

During the year under review, no amount was transferred to general reserves.

OPERATIONAL REVIEW/AFFAIRS OF THE COMPANY & FUTURE OUTLOOK:

The Financial Highlights are as under:

The Total Income for the Financial Year under review was Rs. 65,120.54 Lakhs as against Rs. 60,300.75 Lakhs in the previous
year. The Total Expenses incurred in the current Financial Year was Rs. 58,779.96 Lakhs as against Rs. 57,345.68 Lakhs in the
previous year.

The profit for the Financial Year under review was Rs. 6,613.47 Lakhs as against profit of Rs.3,053.01 Lakhs in the previous
Financial Year.

CHANGE IN NATURE OF BUSINESS:

There was no change in the nature of business of your company during the FY ended 31 March, 2026.

SHARE CAPITAL:

The authorized share capital of the Company is Rs. 50,00,00,000 divided into 5,00,00,000 equity shares of face value of Rs. 10
/- each. The paid up capital of the Company is Rs. 34,93,93,980/- divided into 3,49,39,398 equity shares of face value of Rs. 10
/- each. The Company had issued 1,68,900 equity shares under ESOP scheme 2016 during the financial year 2025-2026. The
Company had allotted 20,00,000 equity shares pursuant to conversion of convertible warrants issued to Expert Chemicals India
Private Limited, promoter of the Company on 18 September, 2025.

MANAGEMENT'S DISCUSSION AND ANALYSIS:

In terms of the provisions of Regulation 34 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 a
separate section on Management Discussion and Analysis (MDA), which also includes further details on the state of affairs of
the Company, forms part of this Annual Report.

DIVIDEND:

The Board of Directors of the Company has not recommended any dividend for the Financial Year 2025-2026.

ANNUAL RETURN:

Pursuant to the provisions of Sections 134(3)(a) and 92(3) of the Act read with Rule 12(1) of the Companies (Management and
Administration) Rules, 2014, the Annual Return of the Company i.e. Form MGT-7 for FY 2025-26 , is placed on the website of
the Company at
http://www.wanbury.com/.

DEPOSITS:

The Company has not accepted any deposits during the year under review. Further, there are no deposits which remained
unpaid / unclaimed at the beginning or at the end of the year under review.

BOARD OF DIRECTORS AND KEY MANAGERIAL PERSONNEL:

The Board of Directors of the Company consists of the following:

Sr. No.

Name of Directors

Director Identification Number

Category

1

Mr. K. Chandran

00005868

Chairman and Whole-time Director

2

Mr. Mohan Kumar Rayana

07878975

Promoter and Whole-time Director

3

Dr. Anupama Vaidya

02713517

Non-Executive Independent Woman Director

4

Mr. Mridul S. Mehta

10177545

Non-Executive Independent Director

5

Mr. Manojkumar K. Gursahani

01064558

Non-Executive Independent Director

6

Mr. P V. Sankar Dass

06604217

Non-Executive Independent Director

Dr. Anupama Vaidya, Mr. Mridul S. Mehta, Mr. Manojkumar K. Gursahani and Mr. P V. Sankar Dass are Independent Directors
who are not liable to retire by rotation.

The terms and conditions of appointment of the Independent Directors and details of the familiarization programs formulated
to educate the Directors regarding their roles, rights and responsibilities in the Company and the nature of the industry in
which the Company operates, the business model of the Company, etc. are placed on the website of the Company
http://www.wanburv.com/.

In accordance with the provisions of Section 152 (6) of the Act and the Articles of Association of the Company, Mr. K. Chandran,
Whole-time Director, who has been longest in the office, retires by rotation at the ensuing Annual General Meeting and being
eligible offers himself for re-appointment.

During the year under review, the Company has re-appointed Mr. Manojkumar K. Gursahani as Non-Executive Independent
Director at the Board Meeting held on 10 December, 2025 and regularized at Extra Ordinary General Meeting held on 5 January,
2026.

Further details including date of appointment/retirement/ resignation of directorship & committee membership etc. have been
mentioned in the Corporate Governance Report which is a part of this Report.

In the opinion of the Board, all directors including the directors appointed / re-appointed during the year possess requisite
qualifications, experience and expertise and hold high standards of integrity.

The list of key skills, expertise and core competencies of the Board has been provided in the Corporate Governance Report
which is a part of this Report.

In addition the above mentioned Whole-time Directors, the list of Key Managerial Personnels (KMP's) are as follows:

Sr.No

Name of KMP

Designation

1

Mr. Vinod Verma

Chief Financial Officer

2

Mr. Jitendra J. Gandhi

Company Secretary

Other than this, no Director or Key Managerial Personnel (KMP's) was appointed or has resigned during the year under review.
NUMBER OF MEETINGS OF THE BOARD OF DIRECTORS:

Seven (7) Board Meetings were held during the Financial Year 2025-2026. These meetings were held on 15 May 2025, 23 June
2025, 4 August 2025, 18 September 2025, 13 November, 2025, 10 December 2025, and 5 February, 2026.

BOARD COMMITTEES AND NUMBER OF MEETINGS OF BOARD COMMITTEEES:

As on the date of this report, the Board has the following committees:

1. Audit Committee

2. Stakeholders Relationship Committee

3. Nomination and Remuneration Committee

4. Risk Management Committee

5. Day to Day Affairs Committee

All the recommendations made by the Board Committees, including the Audit Committee, were accepted by the Board.
Meetings of the Board Committees have been provided in the Corporate Governance report which is part of this Report.
DECLARATION BY DIRECTORS INCLUDING INDEPENDENT DIRECTORS:

Independent Directors have given necessary declaration that they meet the criteria of independence as provided in sub-section
(6) of Section 149 of the Companies Act, 2013 read with the Schedules and Rules made thereunder as well as Regulation 16(1)
(b) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and that they continue to comply with the Code
of Conduct laid down under Schedule IV of the Act.

The Directors have further confirmed that they are not debarred from holding the office of director under any SEBI order or under
the order of any such authority.

The Board has taken on record the declarations and confirmations submitted by the Independent Directors after undertaking due
assessment of the veracity of the same. Further all the Independent Director are registered on Independent Director Database
and hold valid membership.

In the opinion of the Board, the Independent Directors have integrity and sufficient expertise and experience including the
proficiency.

The details including the meetings of the independent directors, familiarisation programme etc. have been provided in the
Corporate Governance Report.

ANNUAL PERFORMANCE EVALUATION:

The Company has devised a policy for performance evaluation of Independent Directors, Board, Committees and other Individual
Directors which includes criteria for performance evaluation of the Non-Executive Directors and Executive Directors.

The Company follows the best practices prevalent in the industry with respect to evaluation of Board Members.

The Company's Nomination and Remuneration policy covers aspects including but not limited to criteria for determining,
qualifications, positive attributes, independence of a director and other matters as provided under Section 178 of the Companies
Act, 2013 and the Regulation 19 of the SEBI (LODR) Regulations.

PARTICULARS OF LOANS, GUARANTEES AND INVESTMENTS UNDER SECTION 186:

The Company has not given any loans, guarantee and made any investments pursuant to the provisions of Section 186 of
Companies Act, 2013 during the year under review.

DETAILS OF SUBSIDIARIES, HOLDING COMPANY, ASSOCIATES AND JOINT VENTURE COMPANIES:

The Company is not having any Subsidiaries, Holding Company, Joint Venture or any Associate Company. However pursuant
to proviso to sub-section (3) of Section 129 read with rule 5 of Companies (Accounts) Rules, 2014, Form AOC-1 is annexed to
this report as Annexure-I.

PARTICULARS OF CONTRACTS OR ARRANGEMENTS WITH RELATED PARTIES:

Pursuant to the provisions of Section 188 of Companies Act, 2013, all contracts/ arrangements/transactions entered into by the
Company during the Financial Year with related parties were in the ordinary course of business and on an arm's length basis.
During the year under review, the Company had not entered into any contract/arrangement/ transaction with related parties,
which could be considered material in accordance with the policy of the Company on materiality of related party transactions.

The transactions entered into with M/s. Wanbury Infotech Private Limited, related party are in the normal course of business and
at arm's length basis. The Policy on materiality of Related Party Transactions and dealing with Related Party Transactions as
approved by the Board may be accessed on the Company's website at
www.wanburv.com.

The details, in specified format in Form AOC-2, of the transactions with the related parties are given in the Annexure - II forming
part of this report.

MATERIAL CHANGES AND COMMITMENTS, IF ANY, AFFECTING THE FINANCIAL POSITION OF THE COMPANY WHICH
HAVE OCCURRED BETWEEN THE FINANCIAL YEAR END OF THE COMPANY TO WHICH FINANCIAL RESULTS RELATE
AND THE DATE OF THIS REPORT:

No material changes and commitments which could affect the Company's financial position have occurred between the end of
the financial year of the Company and date of this report.

STATUTORY AUDITORS:

M/s. Kapoor & Parekh Associates, Chartered Accountants (Firm Registration No. 104803W), Mumbai were appointed as
Statutory Auditors of the Company by the Members vide resolution dated 27 September, 2024 at 36 Annual General Meeting
until the conclusion of the 41 Annual General Meeting.

The Statutory Auditors did not report any instance of fraud committed in the Company by its officers or employees under Section
143(12) of the Act, therefore no details are required to be mentioned in the Board's report.

AUDITOR'S REPORT:

The Notes on Financial Statements referred to in the Auditors Reports for the FY 2026 are self-explanatory and do not call for
any comments and explanation.

The observations made in the Auditor's Report read together with relevant notes thereon are self explanatory and explained
in notes to accounts and hence do not call for any further comments under the Companies Act, 2013. Auditors' Report to the
Shareholders for the year under review does not contain any qualification, reservation or adverse remark or disclaimer.

COST AUDITOR AND COST RECORDS:

The Company have appointed M/s. Manish Shukla & Associates, Cost Accountant, Mumbai as Cost Auditor of the Company for
the Financial Year 2025-2026. M/s. Manish Shukla & Associates, Cost Accountant, Mumbai will submit the Cost Audit Report
alongwith necessary annexure to the Central Government (Ministry of Corporate Affairs) in the prescribed form within specified
time and at the same time forward a copy of such report to our Company

The Cost Audit Report for the Financial Year ended 31 March, 2025 was filed with the Central Government (Ministry of Corporate
Affairs) on 2 September, 2025.

The Cost Auditors did not report any instance of fraud committed in the Company by its officers or employees under Section
143(12) of the Act, the details of which needs to be mentioned in the Board's report.

The Company has maintained cost records as specified under sub-section (1) of section 148 of the Companies Act, 2013, and
accordingly such accounts and records are made and maintained.

ADEQUACY OF INTERNAL FINANCIAL CONTROLS & INTERNAL AUDIT:

Our Company has in place adequate internal financial control systems, commensurate with the size, scale and complexity of its
operations. During the year, such controls were tested and no reportable material weakness in the operations was observed.
The Company has appropriate policies and procedures for ensuring the orderly and efficient conduct of its business, including
adherence of the Company's policies, safeguarding of its assets, prevention and detection of frauds and errors, accuracy and
completeness of accounting records and timely preparation of reliable financial information.

M/s. BDO India LLP, Mumbai, Internal Auditors of the Company, monitors and evaluates the efficacy and adequacy of internal
control systems in the Company. Based on the report of the Internal Auditors, respective departments undertake corrective
action in their respective areas and thereby strengthen the controls. Significant audit observations and corrective actions thereon
are presented to the Audit Committee of the Board.

Our Company has a robust financial closure self-certification mechanism wherein the line managers certify adherence to various
accounting policies, accounting hygiene and accuracy of provisions and other estimates.

SECRETARIAL AUDIT REPORT:

Pursuant to Section 204 of the Act and the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014,
the Board of Directors of the Company has appointed Ms. Kala Agarwal, Practicing Company Secretary [FCS No.: 5976 and
COP No.: 5356] to conduct the Secretarial Audit of the Company for the Financial Year ended on 31 March, 2026 (i.e. from 1
April, 2025 to 31 March, 2026). The Secretarial Audit Report in Form MR-3 is annexed as Annexure - III to this report.

The observations made in the Secretarial Audit Report are as under:

i. According to Regulation 17(1) of the SEBI (LODR) Regulations, 2015, the Company has not complied with the requirements
pertaining to composition of the Board, for the quarter ended March 31, 2025, as observed by the Stock Exchanges vide
its communication dated 29 May, 2025. This has resulted in levy of fine amounting to Rs. 41,300/- (including GST) by BSE
Limited and National Stock Exchanges of India Limited calculated at Rs. 5,000 per day till the date of compliance.

The Company has subsequently complied with the requirement; however, the delay resulted in non-compliance with the
aforesaid regulation.

As per Regulation 17(1)(c) the Composition of Board of Directors should not be less than 6. The Board currently consists
of six Directors.

ii. According to Regulation 19(1)/19(2) of the SEBI (LODR) Regulations, 2015, the Company has not complied with the
requirements pertaining to composition of the Nomination and Remuneration Committee, for the quarter ended March 31,
2025, as observed by the Stock Exchanges vide its communication dated 29 May, 2025. This has resulted into levy of fine
amounting to Rs. 16,520/- (including GST) by BSE Limited and National Stock Exchanges of India Limited calculated at Rs.
2,000 per day till the day of compliance.

The Company has subsequently complied with the requirement; however, the delay resulted in non-compliance with the
aforesaid regulation.

However, the Company has complied with Regulation 19 of the SEBI (LODR) Regulations, 2015, effective from January
8, 2025, upon the appointment of two Non-Executive Independent Directors. The Company has also informed the Stock
Exchanges accordingly.

iii. According to Regulation 31 (1)(b) of the SEBI (LODR) Regulations, 2015, the Company has not filed the Shareholding
Pattern with BSE Limited for the quarter ended September 30, 2025 in stipulated time.

This has resulted into levy of fine amounting to Rs. 42,480- (including GST), calculated at Rs. 2,000 per day till the day of
compliance.

Management Response to the aforesaid observations verbatim are as under:

i. The Company has paid the necessary Penalty aggregating to Rs. 70,000/- (Rs.35,000/- each) to the BSE Limited and
NSE Limited on 5 June, 2025 respectively for non-compliance of Regulation 17(1)( c) of Listing Regulations regarding non¬
composition of Board. However, the Company has complied with the Regulation from 8 January, 2025 onwards.

ii. The Company has paid the necessary Penalty aggregating to Rs. 28,000/- (Rs. 14,000/- each) to the BSE Limited and NSE
Limited on 5 June, 2025 respectively for non-compliance of Regulation 19(a) of Listing Regulations. However, the Company
complied with the Regulation from January 8, 2025, after Mr. Manojkumar Khubchand Gursahani and Mr. Pallavur Sankar
Dass Vaidyanathan were appointed as Non-Executive Independent Directors to the Committee.

iii. The Company has paid the necessary Penalty aggregating to Rs. 36,000/- to the BSE Limited on 21 December, 2025 non¬
compliance of Regulation 31(1)(b) of the Listing Regulations regarding non-filing of Shareholding Pattern within stipulated
time.

The Secretarial Auditors did not report any instance of fraud committed in the Company by its officers or employees under
Section 143(12) of the Act, therefore no details are required to be mentioned in the Board's report.

CORPORATE SOCIAL RESPONSIBILITY POLICY:

Our Company, directly and also through various implementing agencies undertake community interventions to enhance the
lives of the communities. Besides our direct involvement, we partner with numerous implementing agencies to carry out need
assessment and make impactful interventions. Our Focus areas during the year have been;

• Cluster & Rural Development

• Education & Skill Development

• Healthcare Facilities

• Livestock Development

• Tribal Welfare

• Women Empowerment & Livelihood Opportunities

• Water Conservation & Environment sustainability

The above activities are aligned to the requirements of Section 135 of the Act read with Schedule VII.

The detailed policy on Corporate Social Responsibility is available on the website of the Company on the weblink thereto is:
https://www.wanbury.com/policies-andrelated%20documents/

A brief note on various CSR initiatives undertaken during the year including the composition of the CSR Committee is presented
in this Annual report. The CSR Annual Report is annexed as Annexure- B and forms an integral part of the Report.

The details of the composition of the CSR Committee and its term of reference are set out in the Corporate Governance Report,
which is a part of this Report.

Our Company's Audit Committee has been constituted in accordance with the provisions of Section 177 of the Companies Act,
2013 and Regulation 18 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Section 177 of the
Companies Act, 2013.

During the year under review, Four (4) meetings of the Audit Committee were held on 15 May 2025, 4 August 2025,
13 November, 2025 and 5 February, 2026 along with the Board Meetings.

Following are the Members of the Audit Committee:

Sr. No.

Name of Members

Designation

Category

1

Mr. Mridul S. Mehta

Chairperson

I & NED

2

Dr. Anupama Vaidya

Member

I & NED

3

Mr. Manojkumar K. Gursahani

Member

I & NED

4

Mr. P.V. Sankar Dass

Member

I & NED

5

Mr. K. Chandran

Member

WTD

6

Mr. Mohan Kumar Rayana

Member

P & WTD

I = Independent; NED = Non-Executive Director; WTD = Whole-time Director; P = Promoter

The details pertaining to the broad terms and conditions of the Audit Committee are included given in Corporate Governance
Report, which form part of this report.

NOMINATION AND REMUNERATION COMMITTEE:

Nomination and Remuneration Policy inter alia containing appointment criteria, qualifications, positive attributes, independence
of Directors, removal, retirement and remuneration of Directors, Key Managerial Personnel (KMP) and Senior Management
Personnel of the Company has been formulated by the Nomination and Remuneration Committee of the Company and approved
by the Board of Directors.

During the year under review, Six (6) meetings of the Nomination & Remuneration Committee were held on 15 May 2025,
23 June 2025, 4 August 2025, 13 November, 2025, 10 December 2025, and 5 February, 2026.

Following are the Members of the Nomination and Remuneration Committee:

Sr. No.

Name of Members

Designation

Category

1

Dr. Anupama Vaidya

Chairperson

I & NED

2

Mr. Mridul S. Mehta

Member

I & NED

3

Mr. Manojkumar K. Gursahani

Member

I & NED

4

Mr. P.V. Sankar Dass

Member

I & NED

I = Independent; NED = Non-Executive Director; WTD = Whole-time Director; P = Promoter
Nomination and Remuneration Policy is available on the website of the Company at
www.wanburv.com
STAKEHOLDERS RELATIONSHIP COMMITTEE:

Our Company Stakeholder Relationship Committee has been constituted in accordance with the Regulation 20 of SEBI (Listing
Obligations and Disclosure Requirements) Regulations, 2015 in order to specifically look in to the mechanism of Redressal of
grievances of Shareholders.

During the year under review, Four (4) meetings of the Stakeholders Relationship Committee were held on 15 May 2025,
4 August 2025, 13 November, 2025 and 5 February, 2026.

Following are the Members of the Stakeholder Relationship Committee:

Sr. No.

Name of Members

Designation

Category

1

Mr. Manojkumar K. Gursahani

Chairperson

I & NED

2

Dr. Anupama Vaidya

Member

I & NED

3

Mr. Mridul S. Mehta

Member

I & NED

4

Mr. P.V. Sankar Dass

Member

I & NED

5

Mr. K. Chandran

Member

WTD

6

Mr. Mohan Kumar Rayana

Member

P & WTD

I = Independent; NED = Non-Executive Director; WTD = Whole-time Director; P = Promoter

The Board of Directors of the Company has constituted Risk Management Committee to consider the potential risks of the
business of the Company and to plan for the mitigation of the same.

During the year under review, Two (2) meetings of the Risk Management Committee were held on 15.05.2025 & 05.02.2026.
Following are the members of the Risk Management Committee:

Sr. No.

Name of Directors

Designation

Category

1

Mr. P.V. Sankar Dass

Chairperson

I & NED

2

Dr. Anupama Vaidya

Member

I & NED

3

Mr. Mridul S. Mehta

Member

I & NED

4

Mr. Manojkumar K. Gursahani

Member

I & NED

5

Mr. K. Chandran

Member

WTD

6

Mr. Mohan Kumar Rayana

Member

P & WTD

I = Independent; NED = Non-Executive Director; WTD = Whole-time Director; P = Promoter

There is no element of risk which in opinion of the Board threatens the existence of the Company. The risk management policy
as prepared by the Company is available on the website of the Company at
www.wanburv.com.

DAY TO DAY AFFAIRS COMMITTEE:

The Board of Directors of the Company has constituted Day To Day Affairs Committee to consider the potential risks of the
business of the Company and to plan for the mitigation of the same.

Following are the members of the Day to Day affairs Committee:

Sr. No.

Name

Designation

Category

1

Mr. K. Chandran

Chairman

WTD

2

Mr. Mohan Kumar Rayana

Member

WTD

3

Mr. Vinod Verma

Member

CFO

4

Mr. Jitendra J. Gandhi

Member

CS

WTD = Whole-time Director; CS = Company Secretary; CFO = Chief Financial Officer
CORPORATE GOVERNANCE:

In compliance with Regulation 34 (3) read with Schedule V (C) of the SEBI (Listing Obligations and Disclosure Requirements)
Regulations, 2015, a Report on Corporate Governance forms part of this Annual Report. The Auditors' certificate certifying
compliance with the conditions of Corporate Governance as prescribed under Schedule V (E) of the SEBI (Listing Obligations
and Disclosure Requirements) Regulations, 2015 is annexed to the Corporate Governance Report.

PARTICULARS OF EMPLOYEES:

Disclosure pertaining to the remuneration and other details as required under Rule 5(1) of the Companies (Appointment and
Remuneration of Managerial Personnel) Rules, 2014 are attached as Annexure-IV and forms part of this Report.

Information pursuant to Section 197(12) of the Companies Act, 2013 read with Rule 5(2) & 5(3) of the Companies (Appointment
and Remuneration of Managerial Personnel) Rules, 2014 pertaining to the top ten names and other particulars of employees
also form part of this report. However, this information is not sent along with this report pursuant to the proviso to Section 136(1)
of the Act. Any shareholder interested in obtaining a copy of the same may write to the Company Secretary/Compliance Officer
at the Registered office address of the Company and the same will be furnished on request.

SIGNIFICANT AND MATERIAL ORDER PASSED BY THE REGULATORS OR COURTS OR TRIBUNALS IMPACTING THE
GOING CONCERN STATUS AND COMPANY'S OPERATIONS IN FUTURE:

There are no significant and material order passed by the regulators or courts or tribunals impacting the going concern status
and company's operations in future.

VIGIL MECHANISM/ WHISTLE BLOWER POLICY:

The Company, pursuant to Section 177 of the Companies Act, 2013 read along with the rules made thereunder and Regulation
22 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, have established vigil mechanism for Director
and Employees to report concern about unethical behavior, actual or suspected fraud or violation of Company's code of conduct
or ethics policy. The Whistle Blower Policy is posted on the website of the Company at
www.wanbury.com.

SEXUAL HARASSMENT OF WOMEN AT WORKPLACE (PREVENTION, PROHIBITION & REDRESSAL) ACT, 2013:

The Company has in place an Anti Sexual Harassment Policy in line with the requirements of The Sexual Harassment of Women
at Workplace (Prevention, Prohibition & Redressal) Act, 2013. This policy is accessible on the Company's website at
http://www.
wanburv.com/.

Internal Complaints Committee (ICC) has been set up to redress complaints received regarding sexual harassment in a fair and
timely manner. The status of such complaints is periodically reviewed by the Audit Committee to ensure appropriate oversight
and effective redressal mechanisms. All employees (permanent, contractual, temporary, trainees) are covered under this policy.

The Company has not received any sexual harassment complaint during the Financial Year under review.

EMPLOYEE STOCK OPTION SCHEME:

The Company has instituted Employee Stock Option Scheme 2016 (“Wanbury ESOP 2016”) which was approved by the
shareholders vide their resolution dated 29 September, 2016 to reward eligible employees. Pursuant to the said scheme and on
the recommendation of the Nomination and Remuneration Committee, the Board had granted 3,34,000 options to employees
and 2,18,350 options lapsed during the year under review. During the year ended 31 March, 2026, 1,68,900 options were
allotted. 4,11,750 options are outstanding as on 31 March, 2026.

The information required to be disclosed in terms of the provisions of the SEBI (Share Based Employee Benefits and Sweat
Equity Shares) Regulations, 2021 is enclosed as Annexure-V to this report.

SECRETARIAL STANDARDS:

The Directors state that applicable Secretarial Standards, i.e. SS-1 and SS-2, relating to 'Meetings of the Board of Directors' and
'General Meeting' respectively, have been duly followed by the Company.

UNCLAIMED DIVIDEND & SHARES:

Pursuant to the applicable provisions of the Companies Act, 2013, read with the Investor Education and Protection Fund
Authority (Accounting, Audit, Transfer and Refund) Rules, 2016 (the Rules), all unpaid or unclaimed dividends are required to
be transferred by the Company to the IEPF established by the Central Government, after the completion of the seven years.
Further, according to the Rules, the shares on which the dividend has not been paid or claimed by the shareholders for seven
consecutive years or more shall also be transferred to the demat account of the IEPF Authority. Accordingly, the Company has
transferred the unclaimed and unpaid dividend of Rs. 4,14,937/- for the Financial Year 2009-10.

Further, 3,38,465 corresponding shares were transferred as per the requirement of the IEPF Rules. The details are available on
the website, at
www.wanbury.com/PaidUnpaidDividends.

CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION AND FOREIGN EXCHANGE EARNINGS AND OUTGO:

As required by Section 134(3)(m) of the Companies Act, 2013 read with the Companies (Accounts) Rules, 2014 the relevant data
pertaining to conservation of energy, technology absorption and foreign exchange earnings and outgo is given as Annexure - VI
forming part of this report.

APPLICATION OR PROCEEDINGS MADE UNDER THE INDIAN BANKRUPTCY CODE, 2016:

There are no applications or proceedings made under the Indian Bankruptcy Code, 2016.

REASON FOR DIFFERENCE BETWEEN VALUATION DONE AT THE TIME OF TAKING LOAN FROM BANK AND AT THE
TIME OF ONE-TIME SETTLEMENT:

There is one time settlement at the time of taking loan from bank and therefore valuation difference is not applicable.
COMPLIANCE WITH MATERNITY BENEFIT ACT, 1961:

The Company affirms that it has duly complied with all the provision of Maternity Benefits to eligible woman employees during
the year.

DIRECTORS' RESPONSIBILITY STATEMENT:

Pursuant to the provisions of Section 134(3)(c) of the Companies Act, 2013, Directors confirm that:

i. in the preparation of the annual accounts for the Financial Year ended on 31 March, 2026 the applicable accounting
standards had been followed along with proper explanation relating to material departures;

ii. the accounting policies had been selected and applied consistently and made judgments and estimates that are reasonable
and prudent so as to give a true and fair view of the state of affairs of the Company at the end of the Financial Year ended
on 31 March, 2026 and of the profit and loss of the Company for that year;

iii. proper and sufficient care had been taken for the maintenance of adequate accounting records in accordance with the
provisions of the Companies Act, 2013 for safeguarding the assets of the Company and for preventing and detecting fraud
and other irregularities;

iv. the annual accounts had been prepared on a going concern basis;

v internal financial controls, to be followed by the Company, have been laid down and these controls are adequate and were
operating effectively; and the Company has devised proper systems which are in place to ensure compliance with the
provisions of all applicable laws which are considered adequate and are operating effectively.

vi. devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems were
adequate and operating effectively.

US FDA / ANVISA AUDIT:

A) Both the API manufacturing sites are USFDA approved i.e. Patalganga and Tanuku of WL are continued to be compliant
as per cGMP Rules and Regulations with Zero Observation.

During the year under review following audits conducted at Company's plants located at Tanuku, Andhra Pradesh and
Patalganga, Maharashtra.

i) Wanbury Limited's, Andhra Pradesh Tanuku facility has successfully completed the ANVISA (Brazil FDA) inspection
with zero observations. The inspection conducted from December 16, 2024 to December 20, 2024 by the Brazil Health
Regulatory Agency (ANVISA) and confirmed strict adherence to cGMP (Current Good Manufacturing Practices).

ii) Wanbury Limited's, Patalganga manufacturing site of Wanbury has successfully received CBPF (GMP) certificate
from the office of ANVISA (Brazil FDA).

iii) Wanbury Achieves First Sales Invoicing and commercial shipment Milestone on 30 January, 2026 for the new product,
High -Demand Anaesthetic API- Production Ramp-Up Signals Rapid Growth Ahead”.

iv) Sertraline Form II approval received from ANVISA, BRAZIL. This is in addition to Sertraline hydrochloride Form 1
approval that Wanbury already has. WL currently hold 75% market share for sertraline in Brazil's market. Approval
for Form II, will help in further consolidation company's share of business.

v) Patalganga site has completed MFDS (Ministry of Food and Drug Safety - Korea FDA) Regulatory Inspection
successfully. Two inspectors inspected facility for three days i.e. from 7 April 2026 to 9 April, 2026. Inspection
completed with no observation (Zero Observation) confirming cGMP compliance per international rules.

B) Wanbury Limited's API manufacturing site at Tanuku, Andhra Pradesh has successfully completed the Quality inspection by
the TGA, Therapeutic Goods Administration which is a drug regulatory agency of Australia. GMP certificate once received,
will enable Wanbury to ship additional 3 APIs.

C) The company has successfully gone live with its new Rise with SAP S/4 HANA Enterprise Resource Planning (ERP)

system effective October 3, 2025. The migration from SAP ECC system to SAP S/4HANA has been successfully completed
as per schedule, following a structured transition plan and the mandatory blackout days on 1 and 2 October.

The implementation was supported by Deloitte, serving as the strategic partner to enable Wanbury's vision of building an
agile, intelligent, and future-ready enterprise platform.

The new system shall further enhance operational efficiency, transparency, improve productivity, strengthen process
integration across functions, and provide improved data visibility for decision making. It will also serve as a scalable
platform to support the Company's future growth initiatives.

This strategic initiative reinforces the company's commitment to strengthening business operations, enhancing
compliance, and driving greater agility in a rapidly evolving pharmaceutical landscape.

D) Wanbury Limited, a leading pharmaceutical company with a good legacy in domestic branded formulations and global
API markets, proudly announces the successful regional launch of Wanbury C RED, a next-generation Liposomal Iron
formulation mainly designed to revolutionize anemia management in India. This novel formulation leverages liposomal
technology, which ensures enhanced absorption, minimal metallic aftertaste, reduced risk of constipation, and no calcium
chelation thus making it a safe and highly tolerable option for long-term use, especially in pregnant women and iron-
deficient individuals.

E) Wanbury further strengthens its well-known brand - Coriminic, for children cold & sneezing usage, with launch of
Coriminic CPM Drops (Chlorpheniramine Maleate) without combination of decongestant for pediatric/children usage, to
address the drug control notification restricting fixed-dose cold combinations in children under 4 years of age.

Alongside Coriminic CPM Drops, Wanbury is strengthening the Coriminic brand with Coriminic NS (Normal Saline)
Nasal Drops, a non-systemic nasal decongestant solution designed to provide localised relief for children from nasal
congestion, helping physicians navigate treatment options within government regulatory boundaries.

This launch comes in the context of recent advisories and regulatory restrictions issued by the Drugs Controller General of
India (DCGI), which have limited the use of fixed-dose combinations, those containing Chlorpheniramine Phenylephrine,
in children below 4 years due to safety concerns.

GREEN INITIATIVE:

Our Company has adopted green initiative to minimize the impact on the environment. The Company has been circulating
the copy of the Annual Report in electronic format to all those members whose email addresses are available with the
Company. Your Company appeals other Members also to register themselves for receiving Annual Report in electronic
form.

ACKNOWLEDGEMENTS:

Our Company and its Directors wish to extend their sincere thanks to the Bankers, Central & State Government, Customers,
Suppliers, Stakeholders and Staff for their continuous co-operation and guidance and also looking forward for the same in
future.

For and on behalf of the Board of DirectorsK. Chandran Mridul S. Mehta

Whole-time Director Director

Mumbai, 29 May, 2026 DIN:00005868 DIN:10177545